Investigation of genes associated with producing beta-lactamase among Burkholderia cepacia isolates


Burkholderia cepacia has been comprised with numerous individual disorders and is complicated to destroy because of natural resistance to diverse medicines. So, the present investigation proposed to examine the distribution of beta-lactam resistance genes among this bacteria utilizing the PCR method. This work involving 985 patients included 413(43.336%) male and 572(58.071%) female, who were suffering from different infections, However, the specimens collected from Blood, cerebrospinal fluid(C.S.F), Urine, Ear swab, diabetic foot ulcer as well as burn and wound that obtained randomly from main clinical laboratories and the Largest hospitals involved Al-Sader Medical City, and Al-Hakeem General Hospital in Najaf City/Iraq during one year elapsed from September 2018 to end of August 2019. Data revealed 647 (65.685%) bacterial growth distributed as 200(30.911%) and 447(69.088%) for gram-positive and gram-negative bacteria respectively, while 338(34.314%) of cases appeared no growth.
According to biochemical tests and Vitek-2 system B. cepacia were occurred in 16/985(1.624%), these isolates were distributed as following 6(2.5%), 4(7.272%), 3(1.071%), 2(5%) and 1(1.428%) from Burn and wound, diabetic foot ulcer, blood, cerebrospinal fluid., and ear swab respectively, while the bacteria were not detected in urine specimens 0(0%). Drugs of meropenem and minocycline remained more active, 12(75%) and 10(62.5%) of isolates were recorded susceptible respectively, while sensitivity to ceftazidime and Trimethoprim/sulfamethoxazole were 2(12.5%) and 6(37.5%) respectively. Molecular assay of the this work pointed that all 16 (100%) of B. cepacia isolates carried bla-TEM and bla-CTX-M while 15(93%) harbored bla-OXA gene, At same respect, 8(50%) and 4(25%) of isolates were carried the bla-CTX-M-15 and bla-SHV-12 respectively, furthermore, 2(12.5%) of B.cepacia isolates were positive for bla-VEB gene whereas neither of isolates was contained bla-IMI, bla-CepA , and bla-BEL-1.


  • Abbas FA (2017) Antibiotic Susceptibility Patterns of Burkholderia cepacia Isolated from Different Clinical Specimens. Journal of Babylon University/Pure and Applied Sciences, 25(2): 164-144.
  • AL-Dahash H, AL-Charrakh, A, AL-Khafaji J (2013) Characterization of Burkholderia cepacia Isolated from Clinical Samples, in Hilla City, Iraq. Medical Journal of Babylon, 10(2):343-348.
  • Ali M (2016) Burkholderia cepacia in Pharmaceutical Industries. Int J Vaccines Vaccin, 3(2): 00064.
  • Alikhani MY, Tabar Z.K, Mihani F, Kalantar E, Karami P, Sadeghi M, Khosroshahi ShA, Farajnia S (2014) Antimicrobial Resistance Patterns and Prevalence of blaPER-1 and blaVEB-1 Genes Among ESBL-producing Pseudomonas aeruginosa Isolates in West of Iran. Jundishapur J Microbiol,7(1):1-5.
  • Almeida FDS, Avila-Campos MJ (2006) Plasmid-related resistance to Cefoxitin in species of the Bacteroides fragilis group isolated from intestinal tracts of calves. Current, 53,440–443.
  • Bauer AW, Kirby WM, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol, 45(4):493‐496.
  • Bogaerts P, Bauraing C, Deplano A, Glupczynski Y (2007) Emergence and dissemination of BEL-1-producing Pseudomonas aeruginosa isolates in Belgium. Antimicrob. Agents Chemother, 51:1584–1585.
  • Bonacorsi S, Fitoussi F, Lhopital S, Bingen E (1999) Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother,43:213–217.
  • Clontz L (2009) Microbial Limit and Bioburden Tests: Validation Approaches and Global Requirements. 2 ed. CRC Press, Taylor & Francis group LLCP,22p.
  • CLSI (2018) Performance Standards for Antimicrobial Susceptibility Testing, 28th Edition. CLSI Supplement M100. In Clinical and Laboratory Standards Institute, Wayne, PA. 258 p.
  • Corkill JE, Deveney J, Pratt J, Shears P, Smyth A, Heaf D, Hart CA (1994) Effect of pH and CO2 on in vitro susceptibility of Pseudomonas cepacia to beta-lactams. PediatricRes,35:299-302.
  • Dizbay M, Tunccan OG, Sezer B E, Aktas F, Arman D (2009) Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveillance. J Infect DevCtries,3(4):273-277.
  • Eitel Z, Sóki J, Urbán E, Nagy E (2013) the ESCMID Study Group on Anaerobic Infection. The prevalence of antibiotic resistance genes in Bacteroides fragilis group strains isolated in different European countries. Anaerobe, 21:43–9.
  • Ensor VM, Jamal W, Rotimi VO, Evans JT, Hawkey PM (2009) Predominance of CTX-M-15 extended spectrum beta-lactamases in diverse Escherichia coli and Klebsiella pneumoniae from hospital and community patients in Kuwait. Int J Antimicrob Agents, 33:487–489.
  • Ferreira CM, Ferreira WA, Almeida NC, Naveca FG, Barbosa Md (2011) Extended-spectrum beta-lactamase-producing bacteria isolated from hematologic patients in Manaus, State of Amazonas, Brazil. Braz J Microbiol, 42(3):1076‐1084.
  • Hardany MJ , Al-Abdullah AA, Al-Amara SM , Makki HM (2019) Detection ESBL enzymes in gram-negative bacteria. Journal of Basrah Researches ((Sciences)),45(2):53-59.
  • Karami N, Hannoun C, Adlerberth I, Wold A (2008) Colonization dynamics of ampicillin resistant Escherichia coli in the infantile colonic microbiota. Journal of Antimicrobial Chemotherapy,62(4):703–708.
  • Keating D, Schaffer K (2015) 74 Burkholderia cepacia complex infection in an adult cystic fibrosis center over a ten year period. Cystic Fibrosis, J. 14 (1):71-76.
  • Lin SP, Liu M.F, Lin CF, Shi ZY (2011) Phenotypic detection and polymerase chain reaction screening of extended-spectrum β-lactamases produced by Pseudomonas aeruginosa isolates.Journal of Microbiology, Immunology and Infection,45, 200-207.
  • Liu J, Guo-Ming L, Li‑Yao L, Xia‑Lei W, SHao‑Long H, Yong Z, Zu‑Guo Z (2016) Association of antibiotic resistance with SHV-12 extended-spectrum β-lactamase in Enterobactercloacae. Experimental and Therapeutic Medicine,11: 269-276.
  • MacFaddin JF (2000) Biochemical tests for identification of medical bacteria.(3rd edition).The Williams and Wilkins-Baltimor. USA, 928p.
  • Mahenthiralingam E, Baldwin A, Dowson CG (2008) Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol,104:1539-51.
  • Martina PF, Martinez, M, Rivas S, Leguizamón, L, Specht M, and Ferreras J (2019) Burkholderia cepacia complex: 11 years of surveillance in patients with Cystic Fibrosis in Posadas, Argentina. Rev Argent Microbiol, 1-7.
  • Mlynarcik P, Roderova M, Kolar M (2016) Primer Evaluation for PCR and its Application for Detection of Carbapenemases in Enterobacteriaceae. Jundishapur J Microbiol,9(1):e29314.
  • Mushtaq S, Warner M, Livermore DM (2010) In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother, 65:2376-81.
  • Newire EA, Ahmed SF, House B, Valiente E, Pimentel G (2013) Detection of new SHV-12, SHV-5 and SHV-2a variants of extended spectrum Beta-lactamase in Klebsiella pneumoniae in Egypt. Annals of Clinical Microbiology and Antimicrobials,12:16.1-12.
  • Nzula S, Vandamme P, Govan J (2002) Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J. Antimicrob. Chemother, 50:265–269.
  • Ogbolu DO, Daini OA, Ogunledun A., Oyebode AT, Alli OA, Webber MA (2013) Dissemination of IncF plasmids carrying beta-lactamase genes in Gram-negative bacteria from Nigerian hospitals. J Infect DevCtries,7(5):382-390.
  • Peerayeh SN, Elham R, Seyed DS, Safura D (2014) High rate of aminoglycoside resistance in CTX-M-15 producing Klebsiella pneumoniae isolates in Tehran, Iran. Lab Med Summer, 45:231-237 .
  • Poirel L, Brinas L, Verlinde A, Ide L (2005) Nordmann P. BEL-1, anovel clavulanic acid-inhibited extended-spectrum ß-lactamase, and the class1 integron In120 in Pseudomonas aeruginosa. Antimicrob. Agents Chemother, 49:3743–3748.
  • Shlash A, Tuwaij, N (2018) Molecular Dissemination of Ambler Class A and C β- Lactamase Genes among Ceftriaxone Resistant Klebsiella pneumoniae Infection in Najaf City, Iraq. Biochem. Cell. Arch, 18(2):2511–2522.
  • Tseng SP, Tsai WC, Liang CY, Lin Y, Huang J, Chung C, Tyan Y, Lu P (2014) The contribution of antibiotic resistance mechanisms in clinical Burkholderia cepacia complex isolates: an emphasis on efflux pump activity. PLoS One,9(8):e104986.
  • Wigfield SM, Rigg GP, Kavair M, Webb AK, Matthews RC, Burnie, JP (2002) Identification of an immunodominant drug efflux pump in Burkholderia cepacia. J. Antimicrob. Chemother, (49):619–624.
  • Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L (2007) Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother, 51:1085–1088.
  • Ghorbaniparsa F, Ofoghi H (2016) Comparing Patatin Class I and Camv 35s Promoters in Expression of Human Calcitonin Gene in Potato (Solanum Tuberosum Cvs. Kardal And Marfona). The International Journal of Biotechnology, 5(4): 52-61.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.